Targeted Formulations

Kanabo Research continues to develop and medically validate five initial formulations of medical Cannabis extracts for treating Central Nervous System (CNS) disorders. Two of the formulations are already patent pending, and others will be applicable as orphan drugs. The formulations provide the precision and consistency of clinically validated medicine along with the benefits of therapeutic botanical compounds.

Medical Validation

Kanabo Research is reducing uncertainty and risk for its consumers by medically validating their formulations and delivery systems through clinical trials and medical certification with the Israeli Ministry of Health. All clinical trials are developed with data gathered from thousands of medical Cannabis patients. Initial clinical trials focus on sleep disorders and will be concluded in 2018.

Delivery Systems

Kanabo Research partnered with US-based vaporizer company to fill the immediate need for a high-quality, safe, and reliable vaporizer platform. The sophisticated design of the VapePod™ vaporizer, with their CCELL™ ceramic core technology, maintains formulation quality while vaporizing. The vaporizer is in the final stages of certification as a medical device by the Israeli Ministry of Health, and will be available before 2018.